All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-CD22 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD22. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD22 antibody linked to 4-1BB and CD3ζ signaling domains. And the vector product was designed for the treatment of recurrent or refractory B cell acute lymphoblastic leukemia.
CAR Construction : BL22-CD28-CD3ζ, BL22-CD28-41BB-CD3ζ Fig.1 Expression on transduced T cells of CD22 CARs in the second and third-generation constructs. CD22 CARs were detected by CD3-APC (y-axis) and CD22-Fc followed by an anti-IgG-Fc-FITC stain. Percent transduction is noted in the top-right quadrant of each plot. Haso, W., Lee, D. W., Shah, N. N., Stetler-Stevenson, M., Yuan, C. M., Pastan, I. H., ... & Orentas, R. J. (2013). Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood, The Journal of the American Society of Hematology, 121(7), 1165-1174. |
CAR Construction : BL22-CD28-41BB-CD3ζ Fig.2 HA22 and BL22-derived CD22 CARs mediate lytic activity. The lytic activity HA22 and BL22-derived CD22 CARs was compared against ALL cell lines at the indicated E:T ratios in a 4-hour 51Cr-release assay. Haso, W., Lee, D. W., Shah, N. N., Stetler-Stevenson, M., Yuan, C. M., Pastan, I. H., ... & Orentas, R. J. (2013). Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood, The Journal of the American Society of Hematology, 121(7), 1165-1174. |
CAR Construction : Fig.3 Anti-CD22 antibody binding capacity. Anti-CD22 antibody binding capacity per cell quantified in 54 primary patient samples revealed an average CD22 density of 451-16,523 sites per cell (median,4,062). Wayne, A. S., Kreitman, R. J., Findley, H. W., Lew, G., Delbrook, C., Steinberg, S. M., ... & Pastan, I. (2010). Anti-CD22 immunotoxin RFB4 (dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clinical Cancer Research, 16(6), 1894-1903. |
CAR Construction : Fig.4 Equilibrium binding titration curves to determine dissociation constants, KD. MFI (%) of PE is plotted versus the various concentrations of biotinylated CD22-Fc used to label surface-displayed BL22 (WT, KD = 5.8 nM, Bmax = 453), HA22 (KD = 2.5 nM, Bmax = 293), or mutant PT (KD = 1.2 nM, Bmax = 275) antibody. Ho, M., Nagata, S., & Pastan, I. (2006). Isolation of anti-CD22 Fv with high affinity by Fv display on human cells. Proceedings of the National Academy of Sciences, 103(25), 9637-9642. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-CD22 (BL22) h(4-1BB-CD3ζ) CAR, pCDCAR1 (CAR-YF179). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION